Scientific Publications

Search by Keyword(s)
Found 8 results

Filters: Author is Armstrong, SA  [Clear All Filters]

Search Results

  • Showing 1-8 of 8 Results
2014
Requirement for CDK6 in MLL-rearranged acute myeloid leukemia.Placke, T., Faber K., Nonami A., Putwain SL, Salih HR, Heidel FH, Krämer A., Root DE, Barbie DA, Krivtsov AV, Armstrong SA, Hahn WC, Huntly BJ, Sykes SM, Milsom MD, Scholl C., and Fröhling S. Blood, 2014/04/24, (2014) Read More / View Supplemental Materials
Abstract
2013
In Vivo RNAi Screening Identifies a Leukemia-Specific Dependence on Integrin Beta 3 Signaling.Miller, PG, Al-Shahrour F., Hartwell KA, Chu LP, Järås M., Puissant A., McConkey ME, Cowley GS, Shterental S., Alexe G., Armstrong SA, Root DE, Scadden DT, Hynes R. O., Mukherjee S., Stegmaier K., and Ebert BL Cancer cell, 2013/06/11, (2013) Read More / View Supplemental Materials
Abstract
2012
Chromatin-modifying enzymes as modulators of reprogramming.Onder, TT, Kara N., Cherry A., Sinha AU, Zhu N., Bernt KM, Cahan P., Marcarci BO, Unternaehrer J., Gupta PB, Lander E. S., Armstrong SA, and Daley GQ Nature, 2012/03/04, Volume 483, Issue 7391, p.598-602, (2012) Read More / View Supplemental Materials
Abstract
2007
High-throughput oncogene mutation profiling in human cancer.Thomas, RK, Baker AC, Debiasi RM, Winckler W., LaFramboise T., Lin WM, Wang M., Feng W., Zander T., MacConaill L., Lee JC, Nicoletti R., Hatton C., Goyette M., Girard L., Majmudar K., Ziaugra L., Wong KK, Gabriel S., Beroukhim R., et al. Nature genetics, 2007/03/01, Volume 39, Issue 3, p.347-51, (2007) Read More / View Supplemental Materials
Abstract
2006
Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance.Wei, G., Twomey D., Lamb J., Schlis K., Agarwal J., Stam RW, Opferman JT, Sallan SE, den Boer ML, Pieters R., Golub T. R., and Armstrong SA Cancer cell, 2006/10/01, Volume 10, Issue 4, p.331-42, (2006) Read More / View Supplemental Materials
Abstract
The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease.Lamb, J., Crawford ED, Peck D., Modell JW, Blat IC, Wrobel MJ, Lerner J., Brunet JP, Subramanian A., Ross KN, Reich M., Hieronymus H., Wei G., Armstrong SA, Haggarty SJ, Clemons PA, Wei R., Carr SA, Lander E. S., and Golub T. R. Science (New York, N.Y.), 2006/09/29, Volume 313, Issue 5795, p.1929-35, (2006) Read More / View Supplemental Materials
Abstract
Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9.Krivtsov, AV, Twomey D., Feng Z., Stubbs MC, Wang Y., Faber J., Levine JE, Wang J., Hahn WC, Gilliland DG, Golub T. R., and Armstrong SA Nature, 2006/08/17, Volume 442, Issue 7104, p.818-22, (2006) Read More / View Supplemental Materials
Abstract
2005
Conditional MLL-CBP targets GMP and models therapy-related myeloproliferative disease.Wang, J., Iwasaki H., Krivtsov A., Febbo PG, Thorner AR, Ernst P., Anastasiadou E., Kutok JL, Kogan SC, Zinkel SS, Fisher JK, Hess JL, Golub T. R., Armstrong SA, Akashi K., and Korsmeyer SJ The EMBO journal, 2005/01/26, Volume 24, Issue 2, p.368-81, (2005) Read More / View Supplemental Materials
Abstract
  • Showing 1-8 of 8 Results